Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular and Renal Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Renin (REN) drug discovery. Select your target modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Renin (REN) Active Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native folding. |
View REN Products |
| Gene Delivery | Renin (REN) Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View REN Products |
| Benchmark Ab | Anti-Renin Recombinant Antibody Recombinant positive control for ELISA, Western Blot, and neutralization assays. |
View REN Products |
| Validator | Renin (REN) siRNA Set For knockdown verification in primary renal or vascular cells. |
View REN Products |
| Related Target A | Angiotensinogen (AGT) The primary physiological substrate cleaved by Renin to generate Angiotensin I. |
View AGT Products |
| Related Target B | Prorenin Receptor (ATP6AP2) Binds both prorenin and renin, amplifying local RAAS activation and non-proteolytic signaling. |
View ATP6AP2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Species Cross-Reactivity (Human vs. Rodent) | Human, Cynomolgus, and Rodent ortholog proteins available with >95% purity for robust pre-clinical screening. |
| Selectivity Over Other Aspartyl Proteases | Homolog screening panel (Cathepsin D, Cathepsin E, BACE1) strictly verified by mass spectrometry to exclude off-target hits. |
| Lack of Reliable Assay Controls | Sequence-verified benchmark antibodies and validated siRNA included for target-specific assay validation. |
| Enzymatic Activity Consistency | Carrier-free, endotoxin-controlled recombinant proteins preserving optimal physiological enzymatic cleavage of AGT. |
Live Renin (REN) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The renin-angiotensin-aldosterone system (RAAS) remains a cornerstone of cardiovascular and renal therapy. While traditional RAAS inhibitors like ACE inhibitors and Angiotensin Receptor Blockers (ARBs) are widely prescribed, Direct Renin Inhibitors (DRIs) target the rate-limiting step of the cascade. The clinical development of small-molecule DRIs (such as Aliskiren) demonstrated significant blood pressure reduction but faced hurdles regarding oral bioavailability and compensatory renin upregulation.
The next wave of Renin-targeted drug discovery is shifting focus toward long-acting therapeutics, including siRNA-mediated knockdown of RAAS components, antisense oligonucleotides (ASOs), and novel small molecules targeting the Prorenin Receptor (PRR) to block both proteolytic and non-proteolytic pathways. Developing these modalities requires highly purified, native-conformation proteins to screen for precise structural disruption and long-duration target engagement.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (DRI) | Novartis, Speedel | Hypertension, Diabetic Nephropathy | High-throughput FRET enzymatic assays requiring active, glycosylated recombinant Renin. |
| RNA Therapeutics (siRNA/ASO) | Alnylam, Ionis Pharmaceuticals | Refractory Hypertension, CKD | Target validation using sequence-verified siRNA and robust qPCR/Western blot controls. |
| Monoclonal Antibodies / Peptides | Academic Institutions, Biotech Startups | Heart Failure, Local Tissue RAAS Diseases | SPR binding affinity assays requiring highly stable, endotoxin-controlled monomeric Renin/Prorenin. |